Reducing the time between doses is feasible in breast cancer chemotherapy
This article has no abstract so we have provided the first paragraph of the full text.
A recent clinical trial (CALGB 9741) has indicated that the administration of chemotherapy every 14 days, as opposed to every 21 days, is beneficial for both disease-free and overall survival. As a result, Fornier et al. have carried out a pilot study of 38 women with early-stage breast carcinoma to assess the feasibility of further reducing the interdose period to 10–11 days.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mal-function of TLRs by SOCSNature Immunology News and Views (01 Feb 2006)
Solar size variationNature News and Views (31 Jul 1980)